AGENDA

ALABAMA MEDICAID AGENCY
PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

May 4, 2022
1:00 p.m. – 3:00 p.m.

1. Opening remarks………………………………………………………………….Chair
2. Approval of February 9, 2022 P&T Committee Meeting minutes……………..Chair
3. Pharmacy program update………………………………………………………..Alabama Medicaid
4. Oral presentations by manufacturers/manufacturers’ representatives
   (prior to each respective class review)
5. Pharmacotherapy class re-reviews…………………UMass Clinical Pharmacy Services
   • Mineralocorticoid (Aldosterone) Receptor Antagonists – AHFS 243220
   • Central Alpha-Agonists – AHFS 240816
   • Direct Vasodilators – AHFS 240820
   • Peripheral Adrenergic Inhibitors – AHFS 240832
   • Hypotensive Agents, Miscellaneous – AHFS 240892
   • Alpha-Adrenergic Blocking Agents – AHFS 242000
   • Beta-Adrenergic Blocking Agents – AHFS 242400
   • Dihydropyridines – AHFS 242808
   • Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892
   • Angiotensin-Converting Enzyme Inhibitors – AHFS 243204
   • Angiotensin II Receptor Antagonists – AHFS 243208
   • Renin Inhibitors – AHFS 243240
   • Loop Diuretics – AHFS 402808
   • Potassium-Sparing Diuretics – AHFS 402816
   • Thiazide Diuretics – AHFS 402820
   • Thiazide-Like Diuretics – AHFS 402824
   • Vasopressin Antagonists – AHFS 402828
   • Diuretics, Miscellaneous – AHFS 402892
   • Alzheimer’s Agents
     o Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)
     o Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)
6. New Business
7. Results of voting announced………………………………………………………….Chair
8. Next meeting dates
   • August 10, 2022
   • November 9, 2022
   • February 8, 2023
   • May 3, 2023
9. Adjourn